Eugene Pietzak, MD, highlights results from a phase 2 study of pembrolizumab plus BCG for patients with very high-risk, BCG-naive high-grade T1 NMIBC who declined upfront radical cystectomy.
Eugene Pietzak, MD
Advertisement
Eugene Pietzak, MD, is a urologic surgeon at Memorial Sloan Kettering Cancer Center in New York, New York.
Articles by Eugene Pietzak, MD
Eugene Pietzak, MD, highlights the background and design of the ongoing phase 3 GAIN trial, exploring the combination of gemcitabine and BCG in BCG-exposed NMIBC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
ARASEC: Clinical Implications and the Role of Multidisciplinary Care
2
NCCN recommends ctDNA-MRD testing to guide adjuvant treatment post-cystectomy
3
European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC
4
Lymph Node Dissection Following Systemic Therapy in MIBC
5